Overview
Work History
Education
Skills
Corporatesocialresponsibility
Hobbies and Interests
Timeline
Generic
NURIA MAJOS ORO

NURIA MAJOS ORO

London

Overview

14
14
years of professional experience

Work History

Senior Director, Global Commercial Product Strategy, Urothelial and Gynaecological Cancer (UC -GYN)

GILEAD SCIENCES
11.2022 - Current
  • Cross-functional team (CFT) lead: successfully led the commercial team (CT) for the development of the Indication Strategic Plan (ISP), and the global CFT launch readiness at 18 and 12 months prior to launch, achieving VP approval and affiliate appreciation
  • Spearheaded a comprehensive global Key Opinion Leader (KOL) strategy, profiled 150 and engaged > 45, created a global council
  • Direct report: Managed a global director as omnichannel lead (via talent marketplace, 50% time): successfully deployed a pre-launch campaign that enhanced visibility and engagement of Gilead in UC and led digital strategy with omnichannel proposal for UC
  • Led Disease Area Strategy for Gynaecological Cancers (cervical, ovarian and endometrial) (GYN-DAS): PC approved action plan

Director, Global Commercial Product Strategy, Breast cancer (BC)- Trodelvy first global launch

GILEAD SCIENCES
02.2021 - 11.2022
  • Led global campaign deliverables and omnichannel strategy with high affiliate secondment and alignment
  • KOL strategy lead: delivered internal and external global launch meetings
  • VP recognized with >15 KOLs; >250 attendees and replicated by over 7 affiliates involving EU5 and mid-size markets
  • TNBC launch readiness, competitive differentiation and commercial assessment lead: localized by EU5 markets

Global Launch Excellence (GLE) Director- Filgotinib first global launch

GILEAD SCIENCES
06.2020 - 02.2021
  • Oversaw launch readiness for ACE mid-size affiliates developing business cases, LE, POA, KPIs and best practice sharing

Marketing lead, Senior Brand Manager, Cancer Immunotherapy - TECENTRIQ launch, Lung Cancer. First ACE launch.

ROCHE PRODUCTS LTD
06.2018 - 06.2020
  • Developed launch campaign, strategy for all-comers, launch meeting and sales training
  • Team achieved >30% MS 2L NSCLC

BUD Ad-interim| Aug-Dec 2019. Marketing lead, Assoc.Director Marketing, Cell therapies. Yescarta first launch ex-US

KITE, A GILEAD COMPANY
08.2019 - 12.2019
  • Successfully executed best launch in EU- +>20% over Sept LE, >70% MS
  • HSJ Part
  • Award 2020 granted to Kite UK
  • Managed brand strategy, led cross-functional team (CFT), KOL lead| launched CART educational forum |>1000 views/mo

Pharmaceutical Advisor, Field team coordinator (TS/MS/Access) Half of Spain| Haematology, Jakavi Launch

NOVARTIS ONCOLOGY & NOVARTIS PHARMACEUTICALS
09.2014 - 05.2016
  • Best Haem Launch NVS Spain | 80% of regional access barriers removed within 6 months, subsequent increase of national sales cap
  • Implemented successful NHS partnership projects improving regional and hospital access times and patient pathways management

Medical Science Liaison, National level Rheumatology and Rare diseases, Secukinumab, Canakinumab

NOVARTIS ONCOLOGY & NOVARTIS PHARMACEUTICALS
05.2013 - 08.2014
  • Led clinical programme optimization for pivotal trials: sites and patient inclusion
  • Prepared early communication plan and listing strategy
  • Mapped and profiled KOLs and led engagement activities
  • Increased awareness and advocacy in first-in-class MoA and molecule
  • Medical lead for the 'BConnected' programme to raise awareness in rheumatological rare diseases and foster referral network

Brand Manager Multiple Sclerosis (MS) | Neurosciences BU (reporting to BUD)

NOVARTIS ONCOLOGY & NOVARTIS PHARMACEUTICALS
05.2013 - 05.2013
  • Developed the commercial strategy for the MS portfolio to strengthen position vs competitors and as lever to Gylenia launch
  • Led CFT taskforce 'Excellence in Tendering' for Extavia achieving+20% of net sales 2013 vs 2011
  • Responsible for supply chain optimization in line with commercial strategy

Health Economics (HE) and Market Access (MA) Manager

NOVARTIS ONCOLOGY & NOVARTIS PHARMACEUTICALS
05.2010 - 05.2012
  • Pipeline/ portfolio: Cardiovascular and metabolism (CVM), Infectious Diseases, Transplants & Autoimmunity
  • Responsible for price and reimbursement (P&R) applications for new launches/indications (value dossier, pricing strategy, economic and budget impact models for heath technology assessment submissions), obtaining P&R timely and within price corridor
  • Developed CVM portfolio lifecycle strategy in collaboration with regulatory affairs aiming to minimize risk of price decrease, achieving a -1,7% adjustment on a CVM product with high risk of - 30% price cut
  • Conducted market access plan and gap analysis for early phase products (from ph II) to inform Region Europe plans
  • In-market Access: Developed Access Brand Plans (BP) and developed health economic (HE) product-specific tools supported by authorship of HE&OR publications (Rubio-Terres C
  • Et al, Rev Esp Quimioter 2012; Sicras-Mainar et al, Med Clin (Ba(rc), 2013; held poster presentations at AES and ISPOR
  • Access lead of CVM 'ITHACA' patient support programme

Education

Post-graduate certificate - Strategic Marketing Leadership

Henley Business School
London
01.2018

Post-graduate degree - Pharmacoeconomics

UPF-IDEC
Barcelona
01.2012

Master of Business Administration - full-time programme & full-time exchange programme

IESE BUSINESS SCHOOL, LONDON BUSINESS SCHOOL
Barcelona, London
01.2010

PhD - Molecular Biology

CENTER FOR GENOMIC REGULATION (CRG) / UNIVERSITAT POMPEU FABRA (UPF) / HENLEY BUSINESS SCHOOL
Barcelona, London
01.2008

Bachelor of Biochemistry -

UNIVERSITAT DE BARCELONA (UB)
Barcelona
01.2003

Bachelor of Pharmacy - Top Honors, Ranked 2nd in class

UNIVERSITAT DE BARCELONA (UB)
Barcelona
01.2001

Skills

  • Core Values Management
  • Team Building and Motivation
  • Key Performance Indicators
  • Administrative Oversight
  • Reporting expertise
  • Organizational Development

Corporatesocialresponsibility

Member of Interlife, a Novartis program to revamp kidney transplant initiatives in Kenya.

Hobbies and Interests

  • Travel
  • Ski
  • Trekking
  • Yoga
  • Opera
  • Mentor for IESE alumni association

Timeline

Senior Director, Global Commercial Product Strategy, Urothelial and Gynaecological Cancer (UC -GYN)

GILEAD SCIENCES
11.2022 - Current

Director, Global Commercial Product Strategy, Breast cancer (BC)- Trodelvy first global launch

GILEAD SCIENCES
02.2021 - 11.2022

Global Launch Excellence (GLE) Director- Filgotinib first global launch

GILEAD SCIENCES
06.2020 - 02.2021

BUD Ad-interim| Aug-Dec 2019. Marketing lead, Assoc.Director Marketing, Cell therapies. Yescarta first launch ex-US

KITE, A GILEAD COMPANY
08.2019 - 12.2019

Marketing lead, Senior Brand Manager, Cancer Immunotherapy - TECENTRIQ launch, Lung Cancer. First ACE launch.

ROCHE PRODUCTS LTD
06.2018 - 06.2020

Pharmaceutical Advisor, Field team coordinator (TS/MS/Access) Half of Spain| Haematology, Jakavi Launch

NOVARTIS ONCOLOGY & NOVARTIS PHARMACEUTICALS
09.2014 - 05.2016

Medical Science Liaison, National level Rheumatology and Rare diseases, Secukinumab, Canakinumab

NOVARTIS ONCOLOGY & NOVARTIS PHARMACEUTICALS
05.2013 - 08.2014

Brand Manager Multiple Sclerosis (MS) | Neurosciences BU (reporting to BUD)

NOVARTIS ONCOLOGY & NOVARTIS PHARMACEUTICALS
05.2013 - 05.2013

Health Economics (HE) and Market Access (MA) Manager

NOVARTIS ONCOLOGY & NOVARTIS PHARMACEUTICALS
05.2010 - 05.2012

Post-graduate certificate - Strategic Marketing Leadership

Henley Business School

Post-graduate degree - Pharmacoeconomics

UPF-IDEC

Master of Business Administration - full-time programme & full-time exchange programme

IESE BUSINESS SCHOOL, LONDON BUSINESS SCHOOL

PhD - Molecular Biology

CENTER FOR GENOMIC REGULATION (CRG) / UNIVERSITAT POMPEU FABRA (UPF) / HENLEY BUSINESS SCHOOL

Bachelor of Biochemistry -

UNIVERSITAT DE BARCELONA (UB)

Bachelor of Pharmacy - Top Honors, Ranked 2nd in class

UNIVERSITAT DE BARCELONA (UB)

Similar Profiles

CREATE PROFILE
NURIA MAJOS ORO